Your browser doesn't support javascript.
loading
The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years.
Friedova, Lucie; Motyl, Jiri; Srpova, Barbora; Oechtering, Johanna; Barro, Christian; Vodehnalova, Karolina; Andelova, Michaela; Noskova, Libuse; Fialová, Lenka; Havrdova, Eva Kubala; Horakova, Dana; Benedict, Ralph Hb; Kuhle, Jens; Uher, Tomas.
  • Friedova L; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic.
  • Motyl J; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic.
  • Srpova B; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic.
  • Oechtering J; Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, Neurologic Clinic and Policlinic, University Hospital and University of Basel, Switzerland.
  • Barro C; Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, Neurologic Clinic and Policlinic, University Hospital and University of Basel, Switzerland.
  • Vodehnalova K; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic.
  • Andelova M; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic.
  • Noskova L; Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • Fialová L; Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • Havrdova EK; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic.
  • Horakova D; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic.
  • Benedict RH; Department of Neurology, University at Buffalo, Buffalo, NY United States.
  • Kuhle J; Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, Neurologic Clinic and Policlinic, University Hospital and University of Basel, Switzerland.
  • Uher T; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00 Prague, Czech Republic. Electronic address: tomas.uher@vfn.cz.
Mult Scler Relat Disord ; 46: 102534, 2020 Nov.
Article en En | MEDLINE | ID: mdl-33032055
ABSTRACT

BACKGROUND:

Neurofilament light chain level in serum (sNfL) and cerebrospinal fluid (CSF-NfL) is a promising biomarker of disease activity in multiple sclerosis (MS). However, predictive value of neurofilaments for development of cognitive decline over long-term follow-up has not been extensively studied.

OBJECTIVE:

To investigate the relationship between early neurofilament levels and cognitive performance after 9-years.

METHODS:

We included 58 MS patients from the SET study. sNfL levels were measured at screening, at 1 and 2 years. CSF-NfL were measured in 36 patients at screening. Cognitive performance was assessed by the Brief International Cognitive Assessment for Multiple Sclerosis and the Paced Auditory Serial Addition Test-3 s at baseline, at 1, 2 and 9 years. Association between neurofilament levels and cognition was analyzed using Spearman´s correlation, logistic regression and mixed models.

RESULTS:

We did not observe associations among early sNfL levels and cross-sectional or longitudinal cognitive measures, except of a trend for association between higher sNfL levels at screening and lower California Verbal Learning Test-II (CVLT-II) scores at year 1 (rho=-0.31, unadjusted p = 0.028). Higher sNfL level was not associated with increased risk of cognitive decline, except of a trend for greater risk of CVLT-II decrease in patients with higher sNfL levels at 1 year (OR=15.8; 95% CI=1.7-147.0; unadjusted p = 0.015). Similar trends were observed for CSF-NfL.

CONCLUSION:

We found only weak association between sNfL levels at disease onset and evolution of cognitive performance over long-term follow-up.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Filamentos Intermedios / Esclerosis Múltiple Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Filamentos Intermedios / Esclerosis Múltiple Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article